Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 12 for:    gadoteridol

Evaluation of Gd Retention in Human Bone and Skin After MultiHance or ProHance Administration Compared With Control

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03108378
Recruitment Status : Recruiting
First Posted : April 11, 2017
Last Update Posted : August 14, 2018
Sponsor:
Information provided by (Responsible Party):
Bracco Diagnostics, Inc

Brief Summary:

Subjects must be scheduled to undergo an orthopedic surgical procedure. Subjects in the non-control group must have previously received an MRI with MultiHance or ProHance with at least 1 month between the last administration and the scheduled surgery. Subjects who have never received MultiHance or ProHance or any other gadolinium agent will also be enrolled. Subjects must have a test of their kidney function (SCr) at the time of the last MRI examination or at the time of enrollment if they never received gadolinium.

A sample of bone and skin will be collected from the scheduled surgery and tested for the amount of gadolinium. An additional sample of skin will be collected for testing the presence of nephrogenic systemic fibrosis (NSF).


Condition or disease Intervention/treatment
Gadolinium Retention Procedure: Surgery

Detailed Description:

Each subject enrolled will already be scheduled to undergo a hip, shoulder or knee replacement, limb amputations or other orthopedic surgical procedures and each subject enrolled in the non-control group will have retrospectively undergone one or more administrations of MultiHance or PROHANCE with the last dose administered at least 1 month before their scheduled surgery. In order to classify the subjects' renal status, the serum creatinine (SCr) value and/or estimated glomerular filtration rate (eGFR) at the time of last MRI with MultiHance or ProHance must be available and collected. The control subjects' documented SCr values will be collected prior to enrollment in the study.

The bone and skin tissue sample(s) collected (during the subjects surgery) will be blinded to gadolinium based contrast agent (GBCA) exposure and sent to a central laboratory where they will be tested for gadolinium (Gd) and other analytes including calcium, phosphorous, sodium, iron, zinc, and potassium. The Gd deposition of the resected bone and skin tissue will be analyzed by Inductively Coupled Plasma Mass Spectroscopy (ICP-MS). The bone and skin tissue will also be analyzed for other analytes using ICP-MS. These sample(s) will be stored at the central laboratory.

A separate sample of the skin tissue collected (during the subjects' surgery) will also be sent to a central dermatopathologist who will be blinded to GBCA exposure and test for any possible NSF related abnormalities. These skin tissue sample(s) will be stored with the central dermatopathology laboratory.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 36 participants
Observational Model: Cohort
Time Perspective: Other
Official Title: A Prospective Multicenter Cohort Study Evaluating the Long Term Retention of Gadolinium in Human Bone and Skin After the Retrospective Administration of MultiHance or ProHance in Comparison With a Control Group Receiving No Exposure to Gadolinium
Study Start Date : October 2014
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Group/Cohort Intervention/treatment
MultiHance Single Dose
Subjects who received a single dose of MultiHance and no other Gd agent and who are also scheduled for orthopedic surgery
Procedure: Surgery
hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures

MultiHance Multiple Dose
Subjects who received multiple doses of MultiHance and no other Gd agent and who are also scheduled for orthopedic surgery
Procedure: Surgery
hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures

ProHance Single Dose
Subjects who received a single dose of ProHance and no other Gd agent and who are also scheduled for orthopedic surgery
Procedure: Surgery
hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures

ProHance Multiple Dose
Subjects who received multiple doses of ProHance and no other Gd agent and who are also scheduled for orthopedic surgery
Procedure: Surgery
hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures

Control Subgroup
Subjects who have not received any Gd agent and who are also scheduled for orthopedic surgery
Procedure: Surgery
hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures




Primary Outcome Measures :
  1. Gadolinium deposition in bone and skin for non-control group [ Time Frame: At least one month from exposure to GBCA, assessed up to a total of 36 months ]
    Determine the long-term gadolinium deposition in bone tissue and skin in subjects undergoing orthopedic surgery using Inductively Coupled Plasma Mass Spectroscopy (ICP-MS) in nmol gadolinium/g from surgically removed bone and skin.

  2. Gadolinium deposition in bone and skin for control group [ Time Frame: At any time, due to no GBCA exposure, assessed up to a total of 36 months ]
    Determine the long-term gadolinium deposition in bone tissue and skin in subjects undergoing orthopedic surgery using Inductively Coupled Plasma Mass Spectroscopy (ICP-MS) in nmol gadolinium/g from surgically removed bone and skin.


Biospecimen Retention:   Samples Without DNA
Bone & Skin Tissue


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Subjects scheduled to have hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures
Criteria

Inclusion Criteria:

SUBJECTS WHO RECEIVED MULTIHANCE or PROHANCE:

  • Is scheduled to receive hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures
  • Has undergone at least one MULTIHANCE or PROHANCE administration at least 1 month before his/her scheduled surgery
  • Has a documented SCr for calculation of eGFR and/or documented eGFR at time of last MRI with MULTIHANCE or PROHANCE
  • Provides written Informed Consent and is willing to comply with protocol requirements
  • Is willing to undergo deep skin tissue sampling during scheduled hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures
  • Is ≥18 years of age

SUBJECTS WITH NO EXPOSURE TO GBCA:

  • Is scheduled to receive hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures
  • Has no history of GBCA administration
  • Provides written Informed Consent and is willing to comply with protocol requirements
  • Is willing to undergo deep skin tissue sampling during scheduled hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures
  • Has prior SCr and/or eGFR at time of enrollment
  • Is ≥18 years of age

Exclusion Criteria:

SUBJECTS WHO RECEIVED MULTI HANCE or PROHANCE:

  • Has undergone any GBCA including MULTIHANCE or PROHANCE administration less than 1 month before his/her scheduled surgery
  • Has ever been suspected of, or diagnosed with, NSF
  • Has been suspected or diagnosed, prior to inclusion in this study, with bone cancer or any other osteoblastic or osteoclastic disease, such as septic, infectious or ischemic disease affecting physiological bone structure that has caused the bone to be diseased, prior to inclusion in this study
  • Is unable or unwilling to be examined by dermatologists or to undergo laboratory/other diagnostic evaluations should development of NSF be suspected.
  • Has received any GBCA other than the one under evaluation at any time prior to inclusion in this study (e.g., a MULTIHANCE subject should not receive any other GBCA including PROHANCE)

SUBJECTS WITH NO EXPOSURE TO GBCA:

  • Has received any GBCA at any time prior to inclusion in this study
  • Has ever been suspected of, or diagnosed with, NSF prior to the enrollment
  • Has been suspected or diagnosed with bone cancer or any other osteoblastic or osteoclastic disease, such as septic, infectious or ischemic disease affecting physiological bone structure that has caused the bone to be diseased prior to inclusion in this study
  • Is unable or unwilling to be examined by dermatologists or to undergo laboratory/other diagnostic evaluations should development of NSF be suspected.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03108378


Contacts
Layout table for location contacts
Contact: Paola Pianezzola +390221772324 paola.pianezzola@bracco.com
Contact: Kathleen Bensel 609-514-2286 kathleen.bensel@diag.bracco.com

Locations
Layout table for location information
United States, California
VA San Diego Healthcare System Recruiting
San Diego, California, United States, 92161
Contact: Eric Chang, MD         
Sponsors and Collaborators
Bracco Diagnostics, Inc
Investigators
Layout table for investigator information
Study Director: Gianpaolo Pirovano, MD Bracco Diagnostics, Inc

Layout table for additonal information
Responsible Party: Bracco Diagnostics, Inc
ClinicalTrials.gov Identifier: NCT03108378     History of Changes
Other Study ID Numbers: GMRA-102
First Posted: April 11, 2017    Key Record Dates
Last Update Posted: August 14, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Bracco Diagnostics, Inc:
Gadolinium
Bone
Skin